• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award

    5/14/25 4:01:00 PM ET
    $BDSX
    Medical Specialities
    Health Care
    Get the next $BDSX alert in real time by email

    LOUISVILLE, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, is pleased to announce that it is a Colorado Top Workplaces 2025 Winner. The Top Workplaces program has an 18-year history of surveying and celebrating people-first organizations nationally and across 60 regional markets. This recognition is based solely on employee feedback gathered through a third-party survey, administered by employee engagement technology partner, Energage.

    The confidential survey uniquely measures the employee experience and its component themes, including employees feeling respected & supported, enabled to grow, and empowered to execute, to name just a few key attributes of a top-performing workplace.

    "I want to first recognize each of the Biodesix team members for their direct contributions in cultivating our high performing and fulfilling workplace culture," said Scott Hutton, CEO & President of Biodesix, Inc. "As one of only 150 companies to earn this recognition, it reinforces that Biodesix is an employer of choice and reflects our team's enthusiasm to continue building our unique culture. Thank you again to the team for their commitment to excellence in serving our healthcare customers, their patients, and our industry partners as we continue driving towards the Biodesix mission and vision."

    This is the company's second consecutive year being recognized as a great place to work through comprehensive anonymous employee surveys on critical themes measuring employee engagement and workplace culture. Last year, Biodesix received the prestigious Inc. Magazine 2024 Best Workplaces award.

    "In today's market, leaders must ensure they're cultivating a workplace where employees have a voice, and they are heard. Earning a Top Workplaces award is an exclusive badge of honor for companies, especially because it comes authentically from their employees," said Eric Rubino, Energage CEO. "That's something to be very proud of."

    ABOUT BIODESIX

    Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world's leading biopharmaceutical, life sciences tools and diagnostics companies, and academic research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information on our culture and operating principles (Team, Impact, Excellence), please see our website: https://www.biodesix.com/company

    ABOUT ENERGAGE

    Energage is a purpose-driven company that helps organizations turn employee feedback into useful business intelligence and credible employer recognition through Top Workplaces. Built on 18 years of culture research and the results from 27 million employees surveyed across more than 70,000 organizations, Energage delivers the most accurate competitive benchmark available. For more information, visit energage.com or topworkplaces.com.

    Contacts:

    Media:

    Natalie St. Denis, Director Corporate Communications, Biodesix

    [email protected]

    +1 (720) 925-9285

    Investors:

    Chris Brinzey, Partner, Westwicke Group

    [email protected]

    +1 (339) 970-2843



    Primary Logo

    Get the next $BDSX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDSX

    DatePrice TargetRatingAnalyst
    5/14/2025Outperform → Mkt Perform
    William Blair
    9/16/2024Sector Outperform
    Scotiabank
    7/26/2024$3.00Buy
    Craig Hallum
    5/13/2024$2.80Buy
    TD Cowen
    5/3/2024$3.00Buy
    Lake Street
    11/17/2021$21.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BDSX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Development Officer Pestano Gary Anthony converted options into 1,481 shares and sold $5,445 worth of shares (540 units at $10.08), increasing direct ownership by 11% to 9,387 units (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    2/11/26 6:03:20 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Chief Commercial Officer O'Kane Kieran converted options into 1,600 shares and sold $5,889 worth of shares (584 units at $10.08), increasing direct ownership by 13% to 8,885 units (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    2/11/26 6:03:26 PM ET
    $BDSX
    Medical Specialities
    Health Care

    CFO, Sec'y & Treasurer Cowie Robin Harper sold $9,489 worth of shares (941 units at $10.08) and converted options into 2,584 shares, increasing direct ownership by 12% to 15,297 units (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    2/11/26 6:03:21 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Emeritus Director Schuler Jack W bought $1,180,736 worth of shares (100,000 units at $11.81) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    1/27/26 9:29:02 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Emeritus Director Schuler Jack W bought $903,561 worth of shares (82,465 units at $10.96) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    1/26/26 9:28:57 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Director Schuler Jack W bought $999,997 worth of shares (142,045 units at $7.04) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    9/23/25 9:29:04 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Biodesix downgraded by William Blair

    William Blair downgraded Biodesix from Outperform to Mkt Perform

    5/14/25 8:54:25 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Scotiabank initiated coverage on Biodesix

    Scotiabank initiated coverage of Biodesix with a rating of Sector Outperform

    9/16/24 8:45:16 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Craig Hallum initiated coverage on Biodesix with a new price target

    Craig Hallum initiated coverage of Biodesix with a rating of Buy and set a new price target of $3.00

    7/26/24 7:48:11 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    SEC Filings

    View All

    SEC Form S-8 filed by Biodesix Inc.

    S-8 - BIODESIX INC (0001439725) (Filer)

    2/6/26 4:14:20 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Biodesix Inc.

    SCHEDULE 13D/A - BIODESIX INC (0001439725) (Subject)

    1/27/26 2:28:12 PM ET
    $BDSX
    Medical Specialities
    Health Care

    SEC Form SCHEDULE 13G filed by Biodesix Inc.

    SCHEDULE 13G - BIODESIX INC (0001439725) (Subject)

    1/26/26 1:59:41 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    LOUISVILLE, Colo., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter and year ended December 31, 2025 after the close of trading on Thursday, February 26. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately t

    2/12/26 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)

    Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025. LOUISVILLE, Colo., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX) (the company), a leading diagnostic solutions company, today announced its preliminary financial results for the fourth quarter and year ended December 31, 2025 (fiscal 2025). The financial results included in this release pertaining to the fourth quarter and fiscal 2025 are preliminary, unaudited, and subject to final review and adjustment. "Biodesix finished 2025 with a strong fourth quarter delivering

    1/12/26 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix to Present New Data at Two Major Upcoming Scientific Meetings

    Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer Development data for a new ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring to be presented at San Antonio Breast Cancer Symposium (SABCS) LOUISVILLE, Ky., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostics solutions company, announces several poster presentations on lung cancer diagnostics and new research on breast cancer diagnostics at upcoming scientific meetings. At the 2025 North American Conference on Lung Cancer (NACLC), December 5 - 7, in Chicago

    12/3/25 8:22:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Leadership Updates

    Live Leadership Updates

    View All

    Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors

    Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company's Board of Directors (Board) and Audit Committee of the Board effective January 3, 2023. Mr. Kennedy brings to Biodesix more than 20 years of broad operating, corporate finance, company creation and investment experience with a specific focus in the healthcare industry. "We are delighted to welcome Lair to Biodesix's Board of Directors," said Scott Hutton, Chief Executive Officer of Biodesix. "He brings a wealth of business experience with a strong background in healthcare and diagnostics. We look fo

    12/16/22 4:01:00 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors

    Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the appointment of Dr. Jon Faiz Kayyem to the company's board of directors. Dr. Kayyem's diverse career spans more than 20 years and includes experience in academia, lean startups, and Fortune 100 companies. He has served in various leadership positions throughout his career including numerous roles at GenMark Diagnostics, including Founder, CEO and President, Chief Scientific Officer, Senior Vice President of Research and Development. Prior to his work at GenMark Diagnostics, Dr. Kayyem served as Director and Founder of Calimmune and was Vice President of Life Sciences a

    12/8/21 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biodesix Inc.

    SC 13G/A - BIODESIX INC (0001439725) (Subject)

    11/13/24 7:30:22 AM ET
    $BDSX
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Biodesix Inc.

    SC 13G - BIODESIX INC (0001439725) (Subject)

    6/24/24 12:16:38 PM ET
    $BDSX
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Biodesix Inc. (Amendment)

    SC 13D/A - BIODESIX INC (0001439725) (Subject)

    5/23/24 7:10:37 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Financials

    Live finance-specific insights

    View All

    Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    LOUISVILLE, Colo., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter and year ended December 31, 2025 after the close of trading on Thursday, February 26. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately t

    2/12/26 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Announces Third Quarter 2025 Results and Highlights

    Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY2025 Total Revenue Guidance to $84-86 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September 30, 2025. "We delivered a strong third quarter with revenue growing 20% to $21.8 million and continued to improve our already strong gross margins to 81%, a 400-basis point increase year-over-year," said Scott Hutton, Chief Exe

    11/3/25 4:01:00 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix to Report Third Quarter 2025 Financial Results on November 3, 2025

    LOUISVILLE, Colo., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter ended September 30, 2025 after the close of trading on Monday, November 3. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours aft

    10/20/25 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care